News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EHVVF - Check out their partnerships...
$EHVVF - Ehave Inc. Providing Value with Key Partnerships.
Ehave Advances MedReleaf Collaboration with Launch of Digital Patient Intake Portal TORONTO, Nov. 1, 2017
https://web.tmxmoney.com/article.php?newsid=6090817082330319&qm_symbol=LEAF
Ehave say about partnership with MedReleaf...
Ehave's technology will be integrating with MedReleaf's patient and physician dashboard that is used to establish baseline patient assessments and track patient-reported symptoms by incorporating a broad panel of clinically-validated surveys into a single digital portal. "The core of our business is focused on improving outcomes for our patients and using advanced data-driven technology to support and validate efficacy in cannabis-based medicine," says Neil Closner, CEO of MedReleaf. This first tool will be integrated with future compliance and reporting offerings co-developed by Ehave and MedReleaf that will empower patients in their treatment plans, help both patients and healthcare practitioners to encourage treatment compliance, and verify treatment outcomes in a reliable and objective manner.
"We're pleased to advance our flagship collaboration with MedReleaf and launch this first product offering for the investigation of cannabis-based therapies," said Prateek Dwivedi, CEO of Ehave. "Our core data management technology allows us to incorporate and centralize any number of validated or novel patient assessments and surveys into various formats such as our Ehave Connect clinician portal, customized Apps, engaging video games, and other digital platforms. The true power of our technology is in our ability to objectively capture patient outcomes in response to therapy, irrespective of the specific condition, format, or therapy. This provides a pathway to clinical validation for emerging treatment modalities such as medical cannabis, where efficacious dosing and administration remains to be established by clinician and regulatory standards."
“We are very excited with our collaboration with Ehave as it provides us with a foundation of employing next generation patient and clinical research data management solutions early on in the research and development phase of our liver disease program,” said Craig Leon, Chief Executive Officer of Revive. “Ehave’s Platform will support our research and clinical decisions and it will allow us to make objective, data-driven decisions throughout the course of our research and may provide unique insights to expand our initiatives with cannabinoids for the potential treatment of liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and fibrosis.”
"Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially since we signed the original Letter of Intent with Ehave. We have a number of different trials in late-stage planning and see multiple opportunities for us to leverage our traditional pharmaceutical expertise in designing and implementing clinical programs, but we also see growing opportunities for us to leverage our existing relationships with Canadian clinicians and take advantage of our existing pharmaceutical sales infrastructure to better serve clinicians and Insurers as it relates to medical cannabis. We and Ehave are in a unique position to generate meaningful product safety and efficacy data in a variety of trial settings in a very efficient and cost-effective way," says Doug Janzen, Chairman and CEO of Aequus. "In our most recent comprehensive physician survey regarding factors that prevent them from recommending medical cannabis products, Canadian clinicians identified the lack of robust clinical data in a real-world setting for such products as a significant limiting factor."
$AHGIF
UNDERVALUED CANNABIS and BLOCKCHAIN company one of the best investments in this sector.
Assets have increased from $2,328,032 -> $28,598,545 for 9 months 2016 vs 2017 and revenue from $143,480 -> $12,822,468 for 9 months 2016 vs 2017.
See projected revenues for 2018 below:
NO CONVERTIBLE NOTES
Share Structure
Market Value1 $86,750,764 a/o Jan 02, 2018
Authorized Shares Unlimited a/o Dec 12, 2017
Outstanding Shares 52,471,278 a/o Dec 14, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 40,998,997 a/o Dec 14, 2017
Par Value Not Available
The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise. The company is well positioned to reinvest internal operating cash flow in its platform over the long term, thus creating an attractive investment profile for its shareholders such as its involvement in BLOCK CHAIN through the acquisition of an intellectual property rights to a Blockchain Mobile Payment Processing Application from Trident Payments LLC
The company is headquartered in San Antonio and has operations in Los Angeles, and Toronto, Canada.
The company's main operations include:
Laboratory Services
Full-service Clinical Laboratory providing toxicology, blood, and pharmacogenetics testing for physicians which includes a recently granted medicare license.
The Company’s Alternate Health Life Sciences operation entail the discovery, research, education and
development, delivery, extraction, and processing of medical cannabis/CBDs and include:
• License holder of medical cannabis/Cannabidiol (“CBD”) medication delivery systems, including
transdermal patches and dissolvable sublingual tablets for nutraceutical application.
• Research & Development activities demonstrating health benefits and expanding additional uses
for medical cannabis/CBDs.
• Development of patent rights including medical cannabis/CBD efficiency testing, data research
and future method patents around treatment protocols of various illnesses and conditions.
• Development of proprietary nutraceutical formulations and mechanisms to support the delivery of
medical cannabis/CBDs.
• ACBD patch division with a leased facility in California and which began production in late
November 2017 with deliveries expected by early 2018
Patient Management Services:
•The CanaPass system is a cloud-based software platform that manages the end-to-end transactions involved with providing safe access to medical and recreational cannabis (where applicable) to eligible patients and customers. The database is accessible by the patient, certified doctors and licensed producers only linked through a seamless Health Insurance Portability and Accountability Act ('HIPAA') compliant ledger, and is used to monitor the individual patient and provide enhanced treatment recommendations, with a focus on improving patient outcomes.
• AHC holds an exclusive license in Canada and non-exclusive license in the United States for the VIPPatient Electronic Medical Records & Practice Management System (“VIP-Patient”) and owns the CanaCard Controlled Substance and Patient Management System (“CanaCard” or “CPMS” “CanaPass” in the United States)
Cannabis Blockchain Transaction Services:
•The CanaPass system is a cloud-based software platform that manages the end-to-end transactions involved with providing safe access to medical cannabis for eligible patients. CanaPass's key features include the ability to view a patient's purchase history and monitor a patient's response to cannabis products, allowing physicians to make recommendation adjustments to improve overall patient outcomes
•The CanaPass system will launch in all nine NAC clinics starting in October, and will also be used in any new locations as NAC expands. The CanaPass system is also developed to support full compliance for the distribution and transactions for recreational cannabis.
•Blockchain Mobile Payment Processing Application allows for payments using crypto currencies.
$AHGIF is well diversified within the cannabis sector with multiple investments as indicated in the following table, Investments included Clover Trail Capital LLC ($7,373,085), Hightimes
Holding Corp ($332,982), and National Access Cannabis Corp ($1,636,920).
Company is dual listed on OTCQB and CSE and the American Medical Marijuana Physicians Association Endorses Alternate Health's CanaPass Patient Management System With over 650 physician members, AMMPA is a leader in providing physicians with comprehensive support in education, compliance and legal advocacy
References:
https://www.otcmarkets.com/stock/AHGIF/news/Alternate-Health-Launches-First-Ever-Cannabis-Blockchain-Transaction-Ledger?id=170926&b=y
https://www.otcmarkets.com/stock/AHGIF/news/American-Medical-Marijuana-Physicians-Association-Endorses-Alternate-Health-s-CanaPass-Patient-Management-System?id=170653&b=y
https://www.otcmarkets.com/financialReportViewer?symbol=AHGIF&id=183610
https://www.otcmarkets.com/financialReportViewer?symbol=AHGIF&id=183613
https://www.otcmarkets.com/stock/AHGIF/news/Alternate-Health-Corp--Projects--75-Million-in-Revenue?id=172243&b=y
